Cigna's Evernorth unit is expanding coverage for Neuronetics' therapy for depression to adolescents. | Cigna's Evernorth unit ...
The expansion is effective immediately, nearly one year after NeuroStar ® Advanced Therapy received FDA clearance as the first first-line add-on treatment for adolescents aged 15-21 with MDD. In the ...
Hosted on MSN6mon
Neuronetics Expands TMS Coverage, Enhancing Access for MDD TreatmentMALVERN, PA — Neuronetics, Inc. (NASDAQ: STIM) this week announced significant progress in expanding access to its NeuroStar TMS Therapy for patients with major depressive disorder (MDD).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results